 Home > Active Ingredient News > Study of Nervous System > Mov Disord-After ten years of follow-up, how does the movement, cognition and imaging of Huntington patients change?

Mov Disord-After ten years of follow-up, how does the movement, cognition and imaging of Huntington patients change?

 Last Update: 2021-08-14
 Source: Internet
 Author: User

Tags

long chickenpox

long engineering

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Huntington's disease (HD) is a neurodegenerative disease caused by the autosomal dominant amplification of the cytidine-adenine (CAG) fragment in the Huntington (HTT) gene, resulting in the gradual decline of motor, cognitive and mental functions As a feature

HD was first marked by a long asymptomatic pre-stage, which lasted for decades, followed by a comprehensive manifestation of the severity of the disease

Therefore, one of the most critical obstacles to effective new clinical trials is how to assign heterogeneous individuals to homogeneous subgroups

Finding the best window for future drug intervention and determining effective HD stratification will be of great significance to the development of treatment

This method can conduct research on a more representative sample of the HD population and conduct cross-study verification to improve the robustness of the results

In this way, Pubu M.

They combined the clinical and morphological imaging data of 1082 participants in the IMAGE-HD, TRACK-HD, and PREDICT-HD studies, with a longitudinal duration of 1-10 years

They found that the volume of the putamen and the caudate nucleus group can distinguish the age group of CAG, and it is the best variable that can reflect the progress

If only the volume of the caudate nucleus is used, the statistical model can best describe the advanced disease progression in the comprehensive data

The important significance of this study lies in the discovery: During the entire study process, monitoring volume changes, together with primary and secondary clinical endpoints, helps increase people’s awareness of the improvement of functional outcomes, and helps to improve clinical trials.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Quality Pregabalin 99% powder 148553-50-8 -Shaanxi Dideu Medichem Co.Ltd

CAS No.: 148553-50-8

Chemical Grade

$1/KG FOB

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.